https://www.selleckchem.com/pr....oducts/tyloxapol.htm
progression free survival remains the most common endpoint in phase III trials. The association of primary oncologist specialty, medical oncology versus gynecologic oncology, on intensity of care at the end of life in elderly patients with gynecologic cancer is unclear. This retrospective cohort study used Surveillance, Epidemiology and End Results-Medicare (SEER-M) data. Subjects were fee-for-service Medicare enrollees aged 65 years and older who died of a gynecologic cancer between January 2006 and December 2015. The primary outcome
Curtir
Comentario
Compartilhar
